


Antileishmanial agent-13

Cat. No.:	HY-151935
CAS No.:	853725-86-7
Molecular Formula:	C ₁₇ H ₁₀ BrClN ₄ O
Molecular Weight:	401.64
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antileishmanial agent-13 is a quinoline-isatin hybrid, acts as an antileishmanial agent against L. Major Leishmania strain. Antileishmanial agent-13 acquires the antileishmanial activity via the anti-folate mechanism. Antileishmanial agent-13 has potent inhibition against both promastigote and amastigote forms with IC ₅₀ s of 0.604 μM and 0.508 μM, respectively ^[1] .
IC₅₀ & Target	Leishmania
In Vitro	<p>Antileishmanial agent-13 (compound 4e) shows promising in vitro activity against the promastigote superior to Miltefosine (HY-13685) (IC₅₀=7.8976 μM)^[1].</p> <p>Antileishmanial agent-13 (2 μM; 48 h) shows antileishmanial activity mostly attributing to the anti-folate mechanism, via inhibiting DHFR-TS and PTR1^[1].</p> <p>Antileishmanial agent-13 (0-100 μM; 72 h) has low cytotoxicity against African green monkey kidney cells (VERO cells) with CC50 value of 155.8 μM^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Sabt A, et al. New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: Design, synthesis, and molecular modeling studies[J]. European Journal of Medicinal Chemistry, 2022: 114959.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA